Country: United States
Language: English
Source: NLM (National Library of Medicine)
BALSALAZIDE DISODIUM (UNII: 1XL6BJI034) (BALSALAZIDE - UNII:P80AL8J7ZP)
Bryant Ranch Prepack
ORAL
PRESCRIPTION DRUG
Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Limitations of Use Safety and effectiveness of balsalazide beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established. Balsalazide disodium capsules is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the components of balsalazide disodium capsules or balsalazide metabolites [see Warnings and Precautions (5.3), Adverse Reactions (6.2), Description (11)]. Risk Summary Published data from meta-analyses, cohort studies and case series on the use of mesalamine, the active moiety of balsalazide, during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in
NDC: 63629-8301-2: 90 Capsules in a BOTTLE NDC: 63629-8301-1: 30 Capsules in a BOTTLE
Abbreviated New Drug Application
BALSALAZIDE DISODIUM- BALSALAZIDE DISODIUM CAPSULE BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BALSALAZIDE DISODIUM CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BALSALAZIDE DISODIUM CAPSULES. BALSALAZIDE DISODIUM CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 2000 RECENT MAJOR CHANGES Dosage and Administration, Important Administration Instructions (2.1) 10/2020 Warnings and Precautions, Mesalamine-Induced Acute Intolerance Syndrome (5.2) 10/2020 Hypersensitivity Reactions (5.3) 10/2020 Hepatic Failure (5.4) 10/2020 Photosensitivity (5.6) 10/2020 Nephrolithiasis (5.7) 10/2020 Interference with Laboratory Tests (5.8) 10/2020 INDICATIONS AND USAGE Balsalazide is a locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. (1) Limitations of Use: Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established. (1) DOSAGE AND ADMINISTRATION Administration Instructions Evaluate renal function before initiating therapy with balsalazide disodium capsules. (2.1) Swallow capsules whole. Do not cut, break, crush or chew. (2.1) For patients who cannot swallow intact capsules, the capsules may be opened and sprinkled on applesauce, then chewed and swallowed immediately. (2) Teeth and/or tongue staining may occur when administered sprinkled on applesauce. Drink an adequate amount of fluids. (2, 5.7) Take balsalazide disodium capsules with or without food. (2.1) Dosage _Adults:_ The recommended dosage is 2.25 g (three 750 mg capsules) three times daily for 8 weeks. Some adult patients required treatment for up to 12 weeks in clinical trials. (2.2) _Pediatric Patients 5 Years to 17 Years of Age:_ The recommended dosage is either: 2.25 g (three 750 mg capsules) three times for up to 8 weeks. OR: 750 mg (one capsule) three times daily for up to 8 weeks. (2.2 Read the complete document